Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Editorial Volume 7 Issue 1

Tumor-agnostic Therapy: Shifting the Lens from the Tumor Type to its Molecular Identity

Lina El Murr and Georges El Hachem*

Department of Hematology and Medical Oncology, Saint George Hospital University Medical Center, Beirut, Lebano

*Corresponding Author: Georges El Hachem, Medical Oncologist, Department of Hematology and Medical Oncology at Saint George Hospital University Medical Center, Assistant Professor of Clinical Medicine at University of Balamand, Lebanon.

Received: November 29, 2022; Published: December 01, 2022

Abstract

Science and medicine have witnessed a major shift throughout the years and oncology is no stranger to these changes. The diagnosis of a disease and more specifically of a tumor has evolved from the basic histopathological staining and morphological analysis to a more precise identification of receptors and antibodies implicated in the tumor multiplication and more recently to a more peculiar analysis of genomics and molecular markers.

References

  1. Georges El Hachem. “Personalized Medicine: An Emerging Standard of Treatment “a la carte””. Acta Scientific Cancer Biology6 (2018): 01.
  2. The Cancer Genome Atlas Research Network., Weinstein, J., Collisson, E., et al.“The Cancer Genome Atlas Pan-Cancer analysis project”. Nature Genetics 45 (2013): 1113–1120.
  3. Davis AA., et al. “Complexity of Delivering Precision Medicine: Opportunities and Challenges”. American Society of Clinical Oncology Educational Book 38 (2018): 998-1007.
  4. Domchek SM., et al. “Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study”. Lancet Oncology 9 (2020): 1155-1164.

Citation

Citation: Lina El Murr and Georges El Hachem. “Tumor-agnostic Therapy: Shifting the Lens from the Tumor Type to its Molecular Identity”. Acta Scientific Cancer Biology 7.1 (2023): 01.

Copyright

Copyright: © 2023 Lina El Murr and Georges El Hachem. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In




News and Events


Contact US